Broo.Ns
BROO.NS operates in the Pharmaceuticals industry, focusing on the development and commercialization of pharmaceutical products and medical research, generating revenue primarily through the sale of its drug formulations and research services.
Business. BROO.NS operates in the Pharmaceuticals industry, focusing on the development and commercialization of pharmaceutical products and medical research, generating revenue primarily through the sale of its drug formulations and research services.
At a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
BROO.NS operates in the Pharmaceuticals industry, focusing on the development and commercialization of pharmaceutical products and medical research, generating revenue primarily through the sale of its drug formulations and research services.
BROO.NS has a current ratio of 1.48, indicating moderate liquidity, and a debt-to-equity ratio of 0.08, suggesting a relatively low reliance on debt financing. However, the company's free cash flow is negative at -92.88 million INR, which may signal potential liquidity constraints in the near term. The company's liquidity position is further complicated by a negative net cash position after subtracting total debt, as noted in the risk assessment.
In terms of profitability, BROO.NS reported a net loss of 99.67 million INR, with a return on equity of -10.16% and a return on assets of -8.06%. These figures are below the industry median for profitability metrics, indicating that the company is underperforming relative to its peers in terms of generating returns for shareholders and asset utilization.
The company's revenue is concentrated in a single business segment, with no disclosed geographic diversification. This lack of diversification may expose the company to higher operational and market risks, particularly in the pharmaceuticals industry where regulatory and market conditions can vary significantly by region.
Looking ahead, the company's revenue is expected to remain flat or decline in the next fiscal year, with no significant growth trajectory evident from the current financial data. The operating cash flow of 26.26 million INR is insufficient to cover the capital expenditures of 9.23 million INR, which may necessitate additional financing or cost-cutting measures to maintain operations.
The risk assessment highlights a medium liquidity risk and a low dilution risk. The company's negative net cash position after subtracting total debt is a key flag, suggesting potential challenges in meeting short-term obligations without external financing. The dilution risk is low, with no immediate pressure for share issuance, and the company's diluted shares outstanding are equal to its basic shares, indicating no current dilution potential.
Recent events and filings do not indicate any significant changes in the company's strategic direction or financial structure. The company's 10-K filing and other disclosures do not mention any material events or risks that would significantly alter the current financial outlook.
- BROO.NS is experiencing a net loss and negative return on equity, indicating poor profitability.
- The company's liquidity position is moderate, with a current ratio of 1.48 and a negative net cash position after subtracting total debt.
- Revenue is concentrated in a single business segment, with no geographic diversification disclosed.
- The company's free cash flow is negative, and operating cash flow is insufficient to cover capital expenditures.
- The risk assessment indicates a medium liquidity risk and a low dilution risk.
Bull / Bear case
analysis pipelineIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Estimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- Net cash is negative after subtracting total debt.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Capex To Revenuecapital_expenditure / revenue
- Return On Equitynet_income / total_equity
- Debt To Equity(short_term_debt + long_term_debt) / total_equity
- Cash Conversion Ratiooperating_cash_flow / net_income
- BROO.NS Market data — financials · 2026-05-27